Boehringer Ingelheim Venture Fund co-led the cancer immunotherapy developer's series A round, which also featured Illumina Ventures.

The online insurance provider received $13.5m in a round led by Centauri Fund and backed by MassMutual Ventures, MDI Ventures and Central Capital Ventura.

Repeatome drug developer Rome Therapeutics is based on intellectual property from Massachusetts General Hospital and Icahn School of Medicine at Mount Sinai.

JHU-founded restorative materials technology developer Lifesprout secured $28.5m in a round led by Redmile Group as it looks to move into regenerative medicine.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Medytox-backed restorative materials technology developer Lifesprout secured $28.5m in a round led by Redmile Group as it looks to move into regenerative medicine.

The CreditEase-backed banking services provider is targeting a 2021 initial public offering following a round co-led by V Capital and Shefa Capital.

Otsuka Pharmaceuticals's McQuade Center for Strategic Research and Development backed the psilocybin-based mental health drug developer through the round.

Repeatome drug developer Rome Therapeutics was incubated within GV, which took part in the series A round along with fellow corporate unit Partners Innovation Fund.

The robotics AI technology developer pulled in $36m through a series D round led by SoftBank Vision Fund that included fellow existing investor Qualcomm Ventures.